Literature DB >> 2762226

Short-chain alkyl esters of L-dopa as prodrugs for rectal absorption.

J A Fix1, J Alexander, M Cortese, K Engle, P Leppert, A J Repta.   

Abstract

The bioavailability of L-dopa following rectal administration of a series of short-chain alkyl esters of L-dopa was determined in rats and dogs. The esters were stable (greater than 360 min) to hydrolysis in physiological buffer. In vitro enzymatic hydrolysis of the esters in plasma was species dependent, with the hydrolytic rate being faster in rat plasma (t 1/2 less than 5 min) than dog plasma (t 1/2 = 68-181 min) or human plasma (t 1/2 = 96-238 min). In vivo hydrolysis in dogs, as indicated by the L-dopa plasma profile following intravenous administration of the esters, was very rapid (high extravascular esterase activity). Significant L-dopa bioavailability was observed in rats following rectal administration of the methyl (46%), ethyl (14%), isopropyl (48%), butyl (100%), and 4-hydroxybutyl (13%) esters of L-dopa (rectal L-dopa absorption, less than 5%). In dogs, significant L-dopa bioavailability was also observed for the methyl (28%), isopropyl (30%), butyl (32%), and 4-hydroxybutyl (34%) esters of L-dopa in the presence of carbidopa. The data indicate that these highly water-soluble (greater than 600 mg/ml) esters of L-dopa are potential candidates for controlled-release rectal delivery systems designed to provide more constant plasma L-dopa levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2762226     DOI: 10.1023/a:1015924724973

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Patterns of clinical response and plasma dopa levels in Parkinson's disease.

Authors:  E S Tolosa; W E Martin; H P Cohen; R L Jacobson
Journal:  Neurology       Date:  1975-02       Impact factor: 9.910

2.  Plasma dopa concentrations and the "on-off" effect after chronic treatment of Parkinson's disease.

Authors:  R D Sweet; F H McDowell
Journal:  Neurology       Date:  1974-10       Impact factor: 9.910

3.  L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

Authors:  M D Muenter; G M Tyce
Journal:  Mayo Clin Proc       Date:  1971-04       Impact factor: 7.616

4.  Plasma concentrations of L-dopa and 3-methoxydopa and improvement in clinical ratings and motor performance in patients with Parkinsonism treated with L-dopa alone or in combination with amantadine.

Authors:  J B Pilling; J Baker; L L Iversen; S D Iversen; T Robbins
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-02       Impact factor: 10.154

5.  Studies on the metabolism of D- and L-isomers of 3,4-dihydroxyphenylalanine (DOPA). V. Mechanism of intestinal absorption of D- and L-DOPA-14C in rats.

Authors:  H Shindo; T Komai; K Kawai
Journal:  Chem Pharm Bull (Tokyo)       Date:  1973-09       Impact factor: 1.645

6.  Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.

Authors:  N Quinn; C D Marsden; J D Parkes
Journal:  Lancet       Date:  1982-08-21       Impact factor: 79.321

7.  The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats.

Authors:  P S Leppert; M Cortese; J A Fix
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

8.  Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs.

Authors:  M Inoue; M Morikawa; M Tsuboi; M Sugiura
Journal:  Jpn J Pharmacol       Date:  1979-02

9.  L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease.

Authors:  D R Cooper; C Marrel; H van de Waterbeemd; B Testa; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1987-08       Impact factor: 3.765

10.  New compounds: synthesis of alkyl esters of D,L-dopa.

Authors:  C M Lai; W D Mason
Journal:  J Pharm Sci       Date:  1973-03       Impact factor: 3.534

View more
  4 in total

1.  Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.

Authors:  H D Kao; A Traboulsi; S Itoh; L Dittert; A Hussain
Journal:  Pharm Res       Date:  2000-08       Impact factor: 4.200

Review 2.  Old Drugs, New Delivery Systems in Parkinson's Disease.

Authors:  Harsh V Gupta; Kelly E Lyons; Rajesh Pahwa
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

3.  A comparison of oral and rectal absorption of L-dopa esters in rats and mice.

Authors:  J A Fix; J Alexander; M Cortese; K Engle; P Leppert; A J Repta
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

4.  Effect of Rectal Levodopa Administration: A Case Report.

Authors:  Jolanda M J Vogelzang; Marianne Luinstra; A Wijnand F Rutgers
Journal:  Case Rep Neurol       Date:  2015-10-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.